AA
KRYS icon

AlphaMark Advisors’s Krystal Biotech KRYS Stock Holding History

AlphaMark Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,725
Closed -$314K – 678
2024
Q3 		$314K Sell
1,725
-197
-10% -$38K 0.11% 183
2024
Q2 		$353K Buy
+1,922
New +$323K 0.12% 108
2022
Q4 		– Sell
-10
Closed -$1K – 657
2022
Q3 		$1K Hold
10
– – ﹤0.01% 641
2022
Q2 		$1K Buy
+10
New +$622 ﹤0.01% 591

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AlphaMark Advisors's KRYS Position: Q4 2024 in Review

AlphaMark Advisors sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 1,725 shares — an estimated $314K sold.

AlphaMark Advisors first reported a position in KRYS in Q2 2022 and held it in 4 quarters. The position peaked at $353K in Q2 2024. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

  • AlphaMark Advisors reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 1,725 Krystal Biotech shares in Q4 2024, an estimated $314K.
  • AlphaMark Advisors first reported a position in Krystal Biotech in Q2 2022 and held it in 4 quarters.
  • AlphaMark Advisors's Krystal Biotech position peaked at $353K in Q2 2024.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.